EGFR and neoplasm: Similarly, KRAS mutations in colorectal cancer (CRC) contribute to tumor development (Cancer Genome Atlas 2012) and are associated with poor prognosis and resistance to epidermal growth factor receptor (EGFR)-targeted therapies (Lievre et al. 2006).